Abstract
Circulating tumor cells' (CTC) biomarkers may become indicators for selection of therapy. The presence of androgen receptor (AR)-variant-positive CTCs may be markers indicating the need for switching therapy. Methods for AR-variant mRNA isolation from CTCs and confirmation of expression are critical factors needed for these techniques to be clinically applicable.See related article by Tagawa et al., p. 1880.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1696-1698 |
| Number of pages | 3 |
| Journal | Clinical Cancer Research |
| Volume | 25 |
| Issue number | 6 |
| DOIs | |
| State | Published - 2019 |
Bibliographical note
Publisher Copyright:© 2018 American Association for Cancer Research.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Humans
- Male
- Neoplastic Cells, Circulating
- Prostatic Neoplasms, Castration-Resistant
- RNA, Messenger
- Receptors, Androgen
- Taxoids
PubMed: MeSH publication types
- Comment
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, Non-P.H.S.
- Journal Article
- Research Support, N.I.H., Extramural
Fingerprint
Dive into the research topics of 'Ar-variant–positive CTC: A surrogate for a surrogate for taxane therapy outcome?'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS